BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 26465922)

  • 21. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
    Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
    Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synucleinopathy phenotypes.
    McCann H; Stevens CH; Cartwright H; Halliday GM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
    Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
    Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
    Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
    Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synphilin in normal human brains and in synucleinopathies: studies with new antibodies.
    Murray IJ; Medford MA; Guan HP; Rueter SM; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2003 Feb; 105(2):177-84. PubMed ID: 12536229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
    Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
    J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
    Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
    Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-association of parkin and alpha-synuclein.
    Choi P; Golts N; Snyder H; Chong M; Petrucelli L; Hardy J; Sparkman D; Cochran E; Lee JM; Wolozin B
    Neuroreport; 2001 Sep; 12(13):2839-43. PubMed ID: 11588587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy.
    Nishie M; Mori F; Fujiwara H; Hasegawa M; Yoshimoto M; Iwatsubo T; Takahashi H; Wakabayashi K
    Acta Neuropathol; 2004 Apr; 107(4):292-8. PubMed ID: 14722716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
    Solano SM; Miller DW; Augood SJ; Young AB; Penney JB
    Ann Neurol; 2000 Feb; 47(2):201-10. PubMed ID: 10665491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanding the spectrum of neuronal pathology in multiple system atrophy.
    Cykowski MD; Coon EA; Powell SZ; Jenkins SM; Benarroch EE; Low PA; Schmeichel AM; Parisi JE
    Brain; 2015 Aug; 138(Pt 8):2293-309. PubMed ID: 25981961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.
    Smith WW; Margolis RL; Li X; Troncoso JC; Lee MK; Dawson VL; Dawson TM; Iwatsubo T; Ross CA
    J Neurosci; 2005 Jun; 25(23):5544-52. PubMed ID: 15944382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen.
    Vogt IR; Lees AJ; Evert BO; Klockgether T; Bonin M; Wüllner U
    Exp Neurol; 2006 Jun; 199(2):465-78. PubMed ID: 16626704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition.
    Bandopadhyay R; Kingsbury AE; Muqit MM; Harvey K; Reid AR; Kilford L; Engelender S; Schlossmacher MG; Wood NW; Latchman DS; Harvey RJ; Lees AJ
    Neurobiol Dis; 2005 Nov; 20(2):401-11. PubMed ID: 15894486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of colonic alpha-synuclein pathology in multiple system atrophy.
    Pouclet H; Lebouvier T; Coron E; Rouaud T; Flamant M; Toulgoat F; Roy M; Vavasseur F; Bruley des Varannes S; Neunlist M; Derkinderen P
    Parkinsonism Relat Disord; 2012 Aug; 18(7):893-5. PubMed ID: 22560049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropathology underlying clinical variability in patients with synucleinopathies.
    Halliday GM; Holton JL; Revesz T; Dickson DW
    Acta Neuropathol; 2011 Aug; 122(2):187-204. PubMed ID: 21720849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-synuclein binding to rab3a in multiple system atrophy.
    Dalfó E; Ferrer I
    Neurosci Lett; 2005 May 20-27; 380(1-2):170-5. PubMed ID: 15854772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.